A short-lived hold for Arcellx & Gilead
Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.
Mirati secures an independent future
Mirati raises $300m as its chief exec departs. What’s not to like?
Not the sort of Revolution that EQRX had dreamt of
EQRX had once hoped to disrupt cosy US cancer drug pricing arrangements, but when that model failed the group found that cash was its best asset.
